It is well established that EGFR mutations can significantly predict patient outcome and response to the epidermal growth factor receptor (EGFR) inhibitor gefitinib in Asian patients with advanced NSCLC[17-20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.